Patients who have hypertension in the context of recent stroke. MedDRA version: 8.1 Level: LLT Classification code 10015488 Term: Essential hypertension
Conditions
Interventions
Trade Name: Miacardis
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Research Innovation Services, University of Nottingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients must be 18 years of age or over • Onset date of stroke is less than 5 days. • Systolic BP >140mmHg. • Anterior circulation stroke • Persisting stroke symptoms at time of enrolment or visible corresponding stroke lesion on CT Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Less than 18 years of age • Normotension or hypotension (systolic less than 140mmHg) • Onset date more than 5 days • Coma (Scandinavian Stroke Scale (SSS) <4) • Patients who are of childbearing potential, pregnant or breastfeeding • Known bilateral renal artery stenosis (or unilateral in a single kidney) • GFR < 40 • TIA (defined by symptoms resolved in 24 hours with a normal CT scan) • Posterior circulation stroke • Dysphagia with no enteral access • Chest infection requiring continuous oxygen therapy • COPD requiring regular inhalers/nebulisers (mild COPD requiring PRN bronchodilators permitted) • Known hypersensitivity to telmisartan or angiotensin receptor blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): N/A;Secondary Objective: Secondary:- We will assess markers of inflammation post stroke and after treatment with telmisartan.; Main Objective: Primary:-We will assess what effects telmisartan, an angiotensin receptor antagonist, has on cerebral blood flow (CBF), cerebral perfusion pressure (CPP) and central and peripheral BP, central and peripheral pulse pressure, rate-pressure product, and aortic compliance. | — |
Countries
United Kingdom
Outcome results
None listed